Quotes 5-day view Delayed Nasdaq
01/13/2021
01/14/2021
01/15/2021
01/19/2021
01/20/2021
Date
49.97(c)
51.25(c)
51.95(c)
51.85(c)
50.76 Last
2 324 489
1 317 710
4 324 219
4 221 924
2 833 437 Volume
+1.07% +2.56% +1.37% -0.19% -2.10% Change
Sales 2020
1 960 M - -
Net income 2020
1 510 M - -
Net Debt 2020
3 632 M - -
P/E ratio 2020
20,5x
Yield 2020
0,97%
Sales 2021
2 102 M - -
Net income 2021
1 651 M - -
Net Debt 2021
4 264 M - -
P/E ratio 2021
19,2x
Yield 2021
1,30%
Capitalization
20 125 M 20 125 M -
EV / Sales 2020
12,1x
EV / Sales 2021
11,6x
Nbr of Employees
-
Free-Float
37,0%
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates.
All news about ROYALTY PHARMA PLC
News in other languages on ROYALTY PHARMA PLC
Analyst Recommendations on ROYALTY PHARMA PLC
Quicken Loans parent's shares jump on debut after IPO size slashed
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ROYALTY PHARMA PLC
Short Term Mid-Term Long Term Trends Bullish Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
8
Average target price
51,88 $
Last Close Price
51,85 $
Spread / Highest target
8,00%
Spread / Average Target
0,05%
Spread / Lowest Target
-9,35%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
